Antithrombotic therapy with Transcatheter aortic valve replacement.
anticoagulant
antiplatelet
antithrombotic
thrombosis
transcatheter aortic valve
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
25
05
2023
received:
03
02
2023
accepted:
29
05
2023
medline:
23
10
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
ppublish
Résumé
Aortic valve replacement is a necessary management strategy for patients with severe aortic stenosis. The use of transaortic valve replacement (TAVR) has increased significantly over the last decade and now exceeds traditional surgical aortic valve replacement. Since the valve systems used in TAVR consist of bioprosthetic valve tissue encased in a metal stent frame, antithrombotic therapy recommendations cannot be extrapolated from prior data with differently constructed surgical bioprosthetic or mechanical valves. Data on the use of antithrombotic therapy with TAVR are a rapidly developing area of medicine. Choice of agents depends on several patient factors. Patients undergoing TAVR also have a relatively high incidence of subclinical valve thrombosis. The clinical impact of this phenomenon and the implications for antithrombotic therapy continue to evolve. It is critical for clinicians who treat patients undergoing TAVR to have a firm understanding of practice guidelines, the evolving evidence, and its implications for the use of antithrombotic therapy in these patients.
Substances chimiques
Fibrinolytic Agents
0
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1064-1083Informations de copyright
© 2023 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.
Références
D'Agostino RS, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons adult cardiac surgery database: 2019 update on outcomes and quality. Ann Thorac Surg. 2019;107:24-32.
Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;19:1854-1863.
Nistri S, Basso C, Marzari C, Mormino P, Thiene G. Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. Am J Cardio. 2005;96:718-721.
Eveborn GW, Schirmer H, Heggelund G, Lunde P, Rasmussen K. The evolving epidemiology of valvular aortic stenosis. The Tromsø study. Heart. 2013;99:396-400.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021;143:e72-e227.
Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62:1002-1012.
Barreto-Filho JA, Wang Y, Dodson JA, et al. Trends in aortic valve replacement for elderly patients in the United States, 1999-2011. JAMA. 2013;310:2078-2085.
Starr A, Edwards M, McCord C, Griswold H. Aortic replacement: clinical experience with a semirigid ball-valve prosthesis. Circulation. 1963;27:779-783.
Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006-3008.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.
Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-2198.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-1620.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-1705.
Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;371:1790-1798.
Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321-1331.
Thyregod HGH, Steinbrüchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65:2184-2194.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-1715.
Grube E, Laborde JC, Zickmann B, et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv. 2005;66:465-469.
Lisko Iii JC, Shekiladze N, Sandesara P, Devireddy CM. Transcatheter aortic valve replacement: advances in procedural technology and approaches. Interv Cardiol Clin. 2021;10:565-578.
Goldsweig AM, Tak HJ, Chen LW, et al. The evolving management of aortic valve disease: 5-year trends in SAVR, TAVR, and medical therapy. Am J Cardiol. 2019;124:763-771.
Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76:2492-2516.
Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in TAVR and SAVR in patients with severe isolated aortic stenosis. J Am Coll Cardiol. 2022;80:2054-2056.
Shahian DM, Jacobs JP, Badhwar V, et al. The Society of Throacic Surgeons 2018 adult cardiac surgery risk models: part 1 - background, design, considerations, and model development. Ann Thorac Surg. 2018;105:1411-1418.
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438-1454.
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736-2747.
Généreux P, Piazza N, Alu MC, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol. 2021;77:2717-2746.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;43:561-632.
Puri R, Auffrent V, Rodés-Cabai K. Bioprosthetic valve thrombosis. J Am Coll Cardiol. 2017;69:2193-2211.
Bernelli C, Chieffo A, Montorfano M, et al. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheter aortic valve implantation. J Am Coll Cardiol Intv. 2014;7:140-151.
Dangas GD, Lefèvre T, Kupatt C, et al. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve replacement: the randomized BRAVO-3 trial. J Am Coll Cardiol. 2015;66:2860-2868.
Rao SV. The multidimensionality of cardiovascular procedures. J Am Coll Cardiol. 2015;66:2869-2871.
Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC working group on thrombosis. Eur Heart J. 2018;39:1672-1691.
Noble S, Asgar A, Cartier R, Virmani R, Bonan R. Anatomo-pathological analysis after CoreValve Revalving system implantation. EuroIntervention. 2009;5:78-85.
Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary artery disease and transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74:362-372.
Yerasi C, Rogers T, Forrestal BJ, et al. Transcatheter versus surgical aortic valve replacement in young, low-risk patients with severe aortic stenosis. J Am Coll Cardiol Intv. 2021;14:1169-1180.
Nai Fovino L, Scotti A, Massussi M, et al. Coronary angiography after transcatheter aortic valve replacement (TAVR) to evaluate the risk of coronary access impairment after TAVR-in-TAVR. JAHA. 2020;9:e016446.
Ochial T, Chakravarty T, Yoon SH, et al. Coronary access after TAVR. J Am Coll Cardiol Intv. 2020;13:693-705.
Patterson T, Clayton T, Dodd M, et al. ACTIVATION (PercutAneous coronary inTervention prIor to transcatheter aortic VAlve implantaTION): a randomized clinical trial. J Am Coll Cardiol Intv. 2021;14:1965-1974.
Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108:1772-1776.
Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Card. 2014;174:624-627.
Rodés-Cabau J, Masson J-B, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin + Clopidogrel following Transcatheter aortic valve implantation) randomized clinical trial. J Am Coll Cardiol Intv. 2017;10:1357-1365.
Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;383:1447-1457.
Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPEIN valve. Circulation. 2010;122:62-69.
Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPEIN valve. Circulation. 2011;124:425-433.
Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2014;113:355-360.
Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020;382:1696-1707.
Guedeney P, Sorrentino S, Mesnier J, et al. Single versus dual antiplatelet therapy following TAVR: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol Intv. 2021;14:234-236.
Zhang Y, Shen L, Yang W, He B. Dual antiplatelet therapy vs. single antiplatelet therapy after transcatheter aortic valve replacement: an updated systemic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2021;8:1-15.
Kuno T, Yokoyama Y, Brasoulis A, et al. Duration of antiplatelet therapy following transcatheter aortic valve replacement: systematic review and network meta-analysis. J Am Heart Assoc. 2021;10:e019490.
Nijenhuis VJ, ten Berg JM, Hengstenberg C, et al. Usefulness of clopidogrel loading in patients who under went transcatheter aortic valve implantation (from the BRAVO-3 randomized trial). Am J Cardiol. 2019;123:1494-1500.
Kobari Y, Inohara T, Saito T, et al. Aspirin versus clopidogrel as single antithrombotic therapy after transcatheter aortic valve replacement: insights from OCEAN-TAVI registry. Circ Cardiovasc Interv. 2021;14:e010097.
Oliphant CS, Trevarrow BJ, Dobesh PP. Clopidogrel response variability: review of the literature and practical considerations. J Pharm Pract. 2016;29:26-34.
Gross L, Jochheim D, Nitschke T, et al. Platelet reactivity and early outcomes after transfemoral aortic valve implantation. Thromb Haemost. 2018;118:1832-1838.
Jimenez VA, Tello-Montoliu A, Mareno R, et al. Assessment of platelet REACtivity after transcatheter aortic valve replacement: the REAC-TAVI trial. J Am Coll Cardiol Intv. 2019;12:22-32.
Rodés-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol. 2013;62:2349-2359.
Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126:3041-3053.
Van Mieghem NM, Schipper MEI, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation. 2013;127:2194-2201.
Kahlert P, Al-Rashid F, Dottger P, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation. 2012;126:1245-1255.
Storecky S, Windecker S, Pilgrim T, et al. Cerebrovascular accidents complication transcatheter aoric valve implantation: frequency, timing and impact on outcomes. EuroIntervention. 2012;8:62-70.
Auffret V, Regueiro A, Del Trigo M, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:673-684.
Okuno T, Hagemeyer D, Brugger N, et al. Valvular and nonvalvular atrial fibrillation in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13:2124-2133.
Vora A, Dai D, Matsuoka R, et al. Incidence, management and assocated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic vavle replacement: an analysis from STS/ACC TVT registry. J Am Coll Cardiol Intv. 2018;11:1746-1756.
Mojoli M, Gersh BJ, Barioli A, et al. Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic vale implantation: a systematic review and meta-analysis. Am Heart J. 2017;192:64-75.
Altisent OA-J, Durand E, Muñoz-Garćia AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2016;9:1706-1717.
Kosmidou I, Liu Y, Alu MC, et al. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. J Am Coll Cardiol Intv. 2019;12:1580-1589.
Yokoyama Y, Briasoulis A, Takagi H, Kuno T. Anticoagulation with or without antiplatelet therapy following transcatheter aortic valve replacement for patients with atrial fibrillation: a meta-analysis. Cardio Revasc Med. 2021;24:42-47.
Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. J Am Coll Cardiol Intv. 2017;10:66-74.
Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulation type and outcomes after transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2019;12:1566-1576.
Kawashima H, Watanabe Y, Hioki H, et al. Direct oral anticoagulation versus vitamin K antagonists in patients with atrial fibrillation after TAVR. J Am Coll Cardiol Intv. 2020;13:2587-2597.
Butt JH, De Backer O, Olesen JB, et al. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J. 2021;7:11-19.
Didier R, Lhermusier T, Auffret V, et al. TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? J Am Coll Cardiol Intv. 2021;14:1704-1713.
Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS/ACC TVT registry. J Am Heart Assoc. 2022;11:e023561.
Oliveri F, Montalto C, Tua L, et al. Direct oral anticoagulant or vitamin K antagonist after TAVR: a systematic review and meta-analysis. Int J Cardiol. 2022;365:123-130.
Lee W-C, Shih J-Y, Fang H-Y, et al. Comparing vitamin K antagonists and direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter aortic valve replacement: a meta-analysis. Clin Appl Thromb Hemost. 2023;29:1-7.
Yan J, Liu M, Zhang Y, Yang D, An F. Comparison of efficacy and safety between VKAs and DOACs in patients with atrial fibrillation after transcatheter aortic valve replacement: a systematic review and meta-analysis. Clin Cardiol. 2022;45:1002-1010.
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120-129.
Collet J-P, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43:2783-2797.
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;985:2150-2160.
Park D-W, Ahn J-M, Kang D-Y, et al. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial.
Elbadawi A, Dang AT, Sedhom R, et al. Direct oral anticoagulants versus antiplatelet therapy after transcatheter aortic valve replacement: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2022;15:e012194.
Leetmaa T, Hansson NC, Leipsic J, et al. Early aortic transcatheter valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv. 2015;8:e001596.
Ng ACT, Holmes DR, Mack MJ, et al. Leaflet immobility and thrombosis in transcatheter aortic valve replacement. Eur Heart J. 2020;41:3184-3197.
Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Intev. 2015;8:e001770.
Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics, and treatment outcomes. J Am Coll Cardiol Intv. 2017;10:686-697.
Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am J Cardiol. 2016;68:2059-2069.
Makkar RR, Jilaihawi FH, Chakravarty T, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015-2024.
Pache G, Schoechlin S, Blanke P, et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2016;37:2263-2271.
Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383-2392.
Vollema EM, Kong WKF, Katsanos S, et al. Transcatheter aortic valve thrombosis: the relationship between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke. Eur Heart J. 2017;38:1207-1217.
Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. J Am Coll Cardiol Img. 2017;10:1-11.
Ruile P, Minners J, Breitbart P, et al. Medium-term follow-up of early leaflet thrombosis after transcatheter aortic valve replacement. J Am Coll Cardiol Intv. 2018;11:1164-1171.
Garcia S, Fukui M, Dworak MW, et al. Clinical impact of hypoattenuated leaflet thickening after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2022;15:e011480.
Hein M, Schoechlin S, Schulz U, et al. Long-term follow-up of hypoattenuated leaflet thickening after transcatheter aortic valve replacement. J Am Coll Cardiol. 2022;15:1113-1122.
Yanagisawa R, Tanaka M, Yashima F, et al. Early and late leaflet thrombosis after transcatheter aortic valve replacement: a multicenter initiative from the OCEAN-TAVI registry. Circ Cardiovasc Interv. 2019;12:e007349.
De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:130-139.
Montalescot G, Redheuil A, Vincent F, et al. Apixaban and valve thrombosis after transcatheter aortic valve replacement: the ATLANTIS-4D-CT randomized clinical trial substudy. J Am Coll Cardiol Intv. 2022;15:1794-1804.
Blanke P, Leipsic JA, Popma JJ, et al. Bioprostheitc aortic valve leaflet thickening in the Evolut low risk sub-study. J Am Coll Cardiol. 2020;75:2430-2442.
Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol. 2020;75:3003-3015.
Laschinger JC, Changfu W, Ibrahim NG, Shuren JE. Reduced leaflet motion in bioprosthetic aortic valves - the FDA perspective. N Engl J Med. 2015;373:1996-1998.
Hein M, Minners J, Jander N, et al. Haemodynamic prosthetic valve performance in patients with early leaflet thrombosis after transcatheter aortic valve implantation. Clin Res Cardiol. 2019;108:1017-1024.
Bogyi M, Schernthaner RE, Loewe C, et al. Subclinical leaflet thrombosis after transcatheter aortic valve replacement. J Am Coll Cardiol. 2021;14:2643-2656.
Giustino G, Genereuz P. Subclinical thrombosis of bioprosthetic aortic valves. J Am Coll Cardiol. 2020;75:3016-3019.